CDC: Outbreak of extensively drug-resistant pseudomonas aeruginosa associated with 3 artificial tears products

[Shiloh]

Source: https://www.bnnbloomberg.ca/eye-drop-linked-infections-found-in-four-states-cdc-says-1.1882340

1h ago
Eye Drop-Linked Infections Found in Four States, CDC Says
Madison MullerBloomberg News

(Bloomberg) -- Clusters of infections linked to the use of eye drops have been found in four states, according to US health officials tracking the outbreak that's already led to the death of one person.

At least 35 of 56 cases related to the recalled eye drops have been reported from California, Connecticut, Florida and Utah, according to US Centers for Disease Control and Prevention spokesperson. Eight other states have also tallied infections, the CDC said, with some leading to permanent vision loss.

Concern is rising about the outbreak among people who used artificial tears sold by closely held EzriCare LLC based in Lakewood, New Jersey, according to the CDC. Laboratory testing found drug-resistant bacteria in opened containers of EzriCare eye drops that matched the strain found in patients.

EzriCare did not immediately respond to a request for comment. The company isn't aware of any testing that definitely links its product to the outbreak, but recommends that people discontinue their use of the eye drops, according to a statement...

 

[Shiloh]

Source: https://www.cdc.gov/hai/outbreaks/crpa-artificial-tears.html


Current Update

As of May 15, 2023, CDC, in partnership with state and local health departments, identified 81 patients in 18 states (CA, CO, CT, DE, FL, IL, NC, NJ, NM, NV, NY, OH, PA, SD, TX, UT, WA, WI) with VIM-GES-CRPA, a rare strain of extensively drug-resistant P. aeruginosa. This represents an increase of 13 patients since the last update. Among these 13 patients, 6 (46%) had specimens collected prior to the February 2, 2023, manufacturer recall of products associated with this outbreak. These cases were confirmed after the recall date due to the time it takes for testing to confirm the outbreak strain and because of retrospective reporting of infections. Of the 7 patients who had specimens collected after the recall, most either resided in long-term care facilities with other known cases or reported use of a recalled brand of artificial tears.
Dates of specimen collection were from May 2022 to April 2023. Patients were initially identified from cultures of sputum, bronchial wash, or tracheal aspirate (14); sites related to the eye (e.g., cornea, vitreous; 21); urine (13); other nonsterile sources (3); blood (3); and ear (1); and from rectal swabs (26) collected for surveillance. Adverse outcomes that were associated with clinical (non-surveillance) cultures and reported to public health include 14 patients with vision loss, an additional 4 patients with enucleation (surgical removal of eyeball), and 4 deaths within 30 days of VIM-GES-CRPA clinical culture collection.
Most patients reported using artificial tears. Patients reported over 10 different brands of artificial tears, and some patients used multiple brands. EzriCare Artificial Tears, a preservative-free, over-the-counter product packaged in multidose bottles, was the brand most commonly reported. This was the only common artificial tears product identified across the four healthcare facility clusters. Laboratory testing by CDC identified the presence of VIM-GES-CRPA in opened EzriCare bottles from multiple lots; these bottles were collected from patients with and without eye infections and from two states. VIM-GES-CRPA recovered from opened products match the outbreak strain. Testing of unopened bottles of EzriCare Artificial Tears by FDA identified bacterial contamination; further characterization of the contaminants is ongoing.
Three products have been voluntarily recalled by their manufacturer, Global Pharma (Chennai, India), in association with this outbreak: EzriCare Artificial Tears, Delsam Pharma Artificial Tears, and Delsam Pharma Artificial Ointment. No other products have been linked to this outbreak. Patients and healthcare providers should immediately stop using and discard EzriCare Artificial Tears, Delsam Pharma Artificial Tears, and Delsam Pharma Artificial Ointment.
FDA encourages health care professionals and patients to report adverse events or quality problems with any medicine to FDA’s MedWatch Adverse Event Reporting program. Consumers may also report adverse reactions by contacting FDA’s Consumer Complaint Coordinators.







​